Adult Dosing

Cough

• TABS
• 1 TAB PO q 4-6 hours PRN
• Max: 6 TABS qd

• SYRUP
• 1 teaspoonful (5 mL) SYRUP PO q 4-6 hours PRN
• Max: 6 teaspoonfuls qd

Pediatric Dosing

• Note: Safety and efficacy in pediatric patients < 6 years has not been established

Cough

• TABS
• Child 6-12 yrs: 1/2 TABS PO q 4-6 hours PRN
• Max: 3 TABS qd

• SYRUP
• Child 6-12 yrs: 1/2 teaspoonful (2.5 mL) SYRUP PO q 4-6 hours PRN
• Max: 3 teaspoonfuls qd

[Outline]

• Adult Dosing
• Pediatric Dosing

• Symptomatic relief of cough

• Hypersensitivity to hydrocodone or homatropine methylbromide

• N/A

Renal Dose Adjustment

• Renal impairment: Use with caution; dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Use with caution; dose adjustments not defined

See Supplemental Patient Information

• May be habit forming
• Administration of homatropine/hydrocodone or other narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions and head injuries
• Produces dose-related respiratory depression by directly acting on brain stem respiratory centers
• The respiratory depression properties of the drug may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure

Cautions: Use cautiously in

• Severe hepatic impairment
• Severe renal impairment
• Hypothyroidism
• Addison's disease
• Prostatic hypertrophy/urethral stricture
• Asthma
• Drug abuse
• Narrow-angle glaucoma
• Nursing mother
• Elderly/debilitated patients

Supplemental Patient Information

• Advise patients not to perform any task which requires mental alertness until tolerance is determined

Pregnancy Category:C

Breastfeeding: Safety unknown; because of the potential for possible serious adverse reactions in nursing infants a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

• CNS: Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, psychic dependence, mood changes
• GI: Nausea, vomiting, constipation
• GU: Ureteral spasm, spasm of vesicle sphincters, urinary retention
• RESP: Dose-related respiratory depression
• DERM: Skin rash, pruritus
• MISC: Anaphylaxis

Homatropine

• Anticholinergics, antagonizes acetylcholine receptors; blocks the responses of the sphincter muscle of the iris and ciliary muscle of the lens to cholinergic stimulation, producing mydriasis and cycloplegia
• Metabolism: Unknown
• Excreation: Unknown
• Half-life: Unknown

hydrocodone

• Semisynthetic narcotic antitussive and analgesic; precise mechanism of action is unknown; believed to act directly on the cough center. In excessive doses, depresses respiration
• Mostly metabolized by the liver
• Excreted in urine (50-60% as metabolites, 15% as unchanged drug)
• Half-life: 3.8 +/- 0.3 hrs

US Trade Name(s)

• Tussigon

US Availability

homatropine/hydrocodone (generic)

• SYRUP: [1.5 mg/5 mg]/5mL

Tussigon (homatropine/hydrocodone )

• TABS: 1.5 mg/5 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

ENT

Upper Respiratory Combinations

Pulmonary

Upper Respiratory Combinations

Pricing data from www.DrugStore.com in U.S.A.

• Tussigon 5-1.5 MG TABS [Bottle] (MONARCH PHARMACEUTICALS)
  100 mg = $65.99
  300 mg = $170.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• Homatropine methylbromide 1.5 MG / Hydrocodone Bitartrate 5 MG Oral Tablet (Actavis Totowa LLC)
• Hycodan (homatropine methylbromide 1.5 MG / hydrocodone bitartrate 5 MG) Oral Tablet (Endo Pharmaceuticals Inc.)
• Tussigon (homatropine methylbromide 1.5 MG / hydrocodone bitartrate 5 MG) Oral Tablet (Monarch Pharmaceuticals, Inc.)